

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**偉俊生物科技有限公司**

**Wai Chun Bio-Technology Limited**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 660)**

**CHANGE OF DIRECTOR,  
CHANGE OF AUTHORISED REPRESENTATIVE  
AND SERVICE AGENT  
AND  
CHANGE IN THE COMPOSITION OF BOARD COMMITTEES**

The board of directors (the “**Board**”) of Wai Chun Bio-Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces the following:

**(1) RESIGNATION OF EXECUTIVE DIRECTOR**

Mr. Chan Cheuk Ho (“**Mr. Chan**”) has resigned as an executive director of the Company with effect from 13 March 2023 in order to devote more time to his personal commitments.

Mr. Chan has confirmed that he has no disagreement with the Board and there is no matter that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”) in respect of his resignation.

The Board would like to take this opportunity to express its gratitude to Mr. Chan for his efforts and valuable contributions to the Company during his term of office with the Company.

**(2) APPOINTMENT OF EXECUTIVE DIRECTOR**

Mr. Lam Ka Chun (“**Mr. Lam**”) has been appointed as an executive director of the Company with effect from 13 March 2023.

Mr. Lam, aged 32, has been managing directors of the Company and Wai Chun Group Holdings Limited (stock code: 1013) (a company listed on the Main Board of the Stock Exchange), since 2017 and is responsible for the investment and operation of the listed companies. Mr. Lam served as chief executive officer in various companies from 2011 to 2017 and has accumulated extensive experience in project investment and management. Mr. Lam studied chemistry at Imperial College London from 2009 to 2011.

Mr. Lam has entered into a letter of appointment with the Company as an executive director of the Company for an initial term of two years commencing from 13 March 2023. Mr. Lam will hold office until the first general meeting of the Company after his appointment and will thereafter be subject to retirement by rotation and re-election in accordance with the provisions of the articles of association of the Company. Pursuant to the letter of appointment, Mr. Lam is entitled to receive a director's remuneration of HK\$1,200,000 per annum in addition to the salary payable under his existing employment contract (the "**Employment Contract**") with the Group. Under the Employment Contract, Mr. Lam is entitled to an annual salary of HK\$1,200,000 and an annual double pay equivalent to one month salary. Such remuneration and emoluments were determined with reference to his qualifications, experience, duties and responsibilities with the Company, and the prevailing market conditions.

Mr. Lam is the son of Mr. Lam Ching Kui. As at the date of this announcement, Chinese Success Limited, the substantial shareholder of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**SFO**") and the controlling shareholder of the Company, is wholly owned by Wai Chun Investment Fund. Wai Chun Investment Fund is wholly owned by Mr. Lam Ching Kui.

Save as disclosed above, as at the date of this announcement, Mr. Lam (i) did not hold any position with the Company or other members of the Group; (ii) did not hold any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years preceding the date of this announcement and did not have any other major appointments and professional qualifications; (iii) did not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company; (iv) did not have any interest in the shares of the Company within the meaning of Part XV of the SFO; and (v) had no other information to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities ("**Listing Rules**") on the Stock Exchange.

Save as disclosed above, there are no other matters that need to be brought to the attention of shareholders of the Company in relation to the appointment of Mr. Lam and there is no other information required to be disclosed pursuant to any of the requirements under Rule 13.51(2) of the Listing Rules.

### (3) CHANGE OF AUTHORISED REPRESENTATIVE AND SERVICE AGENT

Mr. Chan has ceased to act as an authorised representative of the Company (the “**Authorised Representative**”) under Rule 3.05 of the Listing Rules and an authorised representative of the Company pursuant to Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) for accepting service of process and notices in Hong Kong (the “**Service Agent**”) with effect from 13 March 2023.

Mr. Lam has been appointed as the Authorised Representative and the Service Agent with effect from 13 March 2023.

### (4) CHANGE IN THE COMPOSITION OF BOARD COMMITTEES

Mr. Chan has ceased to be a member of each of the nomination committee and remuneration committee of the Company with effect from 13 March 2023.

Mr. Lam has been appointed as a member of each of the nomination committee and remuneration committee of the Company with effect from 13 March 2023.

The Board wishes to express its warmest welcome to Mr. Lam on his new appointment.

By Order of the Board  
**Wai Chun Bio-Technology Limited**  
**Lam Ka Chun**  
*Executive Director*

Hong Kong, 13 March 2023

*As at the date of this announcement, the Board consists of one executive Director, namely Mr. Lam Ka Chun and three independent non-executive Directors, namely Ms. Hong Ting, Mr. Wan Bo and Mr. Hung Hoi Ming Raymond.*